-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Peripheral T-cell lymphoma (PTCL) and non-mycosis fungoides (non-MF) Cutaneous T-cell lymphoma (CTCL) is a markedly heterogeneous group of diseases characterized by relatively low cure rates with initial therapy , options for relapsed or refractory disease are limited
lymphoma
Signaling through JAK1 and/or JAK2 is common in both tumor and non-tumor cells of peripheral T-cell lymphoma (PTCL)
This study is a phase 2 study of the JAK1/2 inhibitor ruxolitinib in patients with relapsed or refractory PTCL (n=45) or mycosis fungoides (n=7)
Clinical benefit profiles by cohort and subtype
Clinical benefit profiles by cohort and subtypeOnly 1 of 7 MF patients had clinical benefit (objective response >18 months)
In cohorts 1, 2, and 3 of PTCL cases (n=45), the CBR rates were 53%, 45%, and 13% leukemia , respectively
Treatment effects of different cohorts of PTCL patients
Treatment effects of different cohorts of PTCL patientsIn an exploratory analysis using multiplex immunofluorescence , expression of phosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, in <25% of tumor cells correlated with response to ruxolitinib treatment.
Expression of immunophosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, correlates with responsiveness to ruxolitinib treatment in <25% of tumor cells Phosphorylated S6, a PI3 kinase or markers of mitogen-activated protein kinase activation) expression in <25% of tumor cells correlated with responsiveness to ruxolitinib treatment
In conclusion, this study demonstrates that ruxolitinib has antitumor activity in various PTCL subtypes, suggesting that PTCL patients may be able to employ precision therapeutic strategies for JAK/STAT inhibition
Ruxolitinib has antitumor activity in various PTCL subtypes, suggesting that PTCL patients may be able to adopt precision treatment strategies for JAK/STAT inhibition
Original source:
Alison J.
A phase 2 biomarker-driven study of ruxolitinib demonstrates the effectiveness of JAK/STAT targeting in T-cell lymphomasLeave
a comment here
